Laryngeal preservation for hypopharyngeal cancer by radiotherapy with S-1 and vitamin A (TAR therapy)

Torahiko Nakashima, Satoshi Toh, Hideki Shiratsuchi, Ryuji Yasumatsu, Junichi Fukushima, Katsumasa Nakamura, Yoshiyuki Shioyama, Shizuo Komune

Research output: Contribution to journalArticle

Abstract

The objective of this study was to analyze the outcome of hypopharyngeal cancer patients who underwent triple combination treatment with S-1, vitamin A and radiation (TAR therapy), and to analyze the role of TAR therapy for treating locally advanced hypopharyngeal cancer patients. 146 patients (stage I: 10 cases, stage II: 22 cases, stage III: 23 cases, stage IV: 91 cases) with hypopharyngeal squamous cell carcinoma were treated with TAR therapy (S-1; orally, 65 mg/m2/day, twice a day; vitamin A (retinol palmitate): 50, 000 I U/day, intra-musculary on each day of radiation; radiation: 1.5-2 Gy/day, 5 days/week). Histologic complete responders at 30-40 Gy continued TAR therapy up to 60-70 Gy. Nonresponders at 30-40 Gy underwent surgery. The overall 5-year survival and disease-specific 5-year survival rates were 50.5% and 59% respectively. The cumulative 3-year laryngeal preservation rate for stage I was 100%, 82.5% for stage II, 66.6% for stage III, and 35% for stage IV. Laryngeal preservation was fair in T1/T2 patients (81 %), but not satisfactory in T3/T4 patients (21.4%). S1 is administered orally, and TAR therapy can be conducted in the clinic with low toxicity. However, protocols with high intensity may be necessary to improve laryngeal preservation for locally advanced (T4) hypopharyngeal cancer.

Original languageEnglish
Pages (from-to)759-763
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume39
Issue number5
Publication statusPublished - Jan 1 2012

Fingerprint

Hypopharyngeal Neoplasms
Vitamin A
Radiotherapy
Radiation
Therapeutics
Squamous Cell Carcinoma
Survival Rate
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nakashima, T., Toh, S., Shiratsuchi, H., Yasumatsu, R., Fukushima, J., Nakamura, K., ... Komune, S. (2012). Laryngeal preservation for hypopharyngeal cancer by radiotherapy with S-1 and vitamin A (TAR therapy). Japanese Journal of Cancer and Chemotherapy, 39(5), 759-763.

Laryngeal preservation for hypopharyngeal cancer by radiotherapy with S-1 and vitamin A (TAR therapy). / Nakashima, Torahiko; Toh, Satoshi; Shiratsuchi, Hideki; Yasumatsu, Ryuji; Fukushima, Junichi; Nakamura, Katsumasa; Shioyama, Yoshiyuki; Komune, Shizuo.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 39, No. 5, 01.01.2012, p. 759-763.

Research output: Contribution to journalArticle

Nakashima, T, Toh, S, Shiratsuchi, H, Yasumatsu, R, Fukushima, J, Nakamura, K, Shioyama, Y & Komune, S 2012, 'Laryngeal preservation for hypopharyngeal cancer by radiotherapy with S-1 and vitamin A (TAR therapy)', Japanese Journal of Cancer and Chemotherapy, vol. 39, no. 5, pp. 759-763.
Nakashima, Torahiko ; Toh, Satoshi ; Shiratsuchi, Hideki ; Yasumatsu, Ryuji ; Fukushima, Junichi ; Nakamura, Katsumasa ; Shioyama, Yoshiyuki ; Komune, Shizuo. / Laryngeal preservation for hypopharyngeal cancer by radiotherapy with S-1 and vitamin A (TAR therapy). In: Japanese Journal of Cancer and Chemotherapy. 2012 ; Vol. 39, No. 5. pp. 759-763.
@article{a88a0d4beb2b46528946e6fe2748b1b0,
title = "Laryngeal preservation for hypopharyngeal cancer by radiotherapy with S-1 and vitamin A (TAR therapy)",
abstract = "The objective of this study was to analyze the outcome of hypopharyngeal cancer patients who underwent triple combination treatment with S-1, vitamin A and radiation (TAR therapy), and to analyze the role of TAR therapy for treating locally advanced hypopharyngeal cancer patients. 146 patients (stage I: 10 cases, stage II: 22 cases, stage III: 23 cases, stage IV: 91 cases) with hypopharyngeal squamous cell carcinoma were treated with TAR therapy (S-1; orally, 65 mg/m2/day, twice a day; vitamin A (retinol palmitate): 50, 000 I U/day, intra-musculary on each day of radiation; radiation: 1.5-2 Gy/day, 5 days/week). Histologic complete responders at 30-40 Gy continued TAR therapy up to 60-70 Gy. Nonresponders at 30-40 Gy underwent surgery. The overall 5-year survival and disease-specific 5-year survival rates were 50.5{\%} and 59{\%} respectively. The cumulative 3-year laryngeal preservation rate for stage I was 100{\%}, 82.5{\%} for stage II, 66.6{\%} for stage III, and 35{\%} for stage IV. Laryngeal preservation was fair in T1/T2 patients (81 {\%}), but not satisfactory in T3/T4 patients (21.4{\%}). S1 is administered orally, and TAR therapy can be conducted in the clinic with low toxicity. However, protocols with high intensity may be necessary to improve laryngeal preservation for locally advanced (T4) hypopharyngeal cancer.",
author = "Torahiko Nakashima and Satoshi Toh and Hideki Shiratsuchi and Ryuji Yasumatsu and Junichi Fukushima and Katsumasa Nakamura and Yoshiyuki Shioyama and Shizuo Komune",
year = "2012",
month = "1",
day = "1",
language = "English",
volume = "39",
pages = "759--763",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "5",

}

TY - JOUR

T1 - Laryngeal preservation for hypopharyngeal cancer by radiotherapy with S-1 and vitamin A (TAR therapy)

AU - Nakashima, Torahiko

AU - Toh, Satoshi

AU - Shiratsuchi, Hideki

AU - Yasumatsu, Ryuji

AU - Fukushima, Junichi

AU - Nakamura, Katsumasa

AU - Shioyama, Yoshiyuki

AU - Komune, Shizuo

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The objective of this study was to analyze the outcome of hypopharyngeal cancer patients who underwent triple combination treatment with S-1, vitamin A and radiation (TAR therapy), and to analyze the role of TAR therapy for treating locally advanced hypopharyngeal cancer patients. 146 patients (stage I: 10 cases, stage II: 22 cases, stage III: 23 cases, stage IV: 91 cases) with hypopharyngeal squamous cell carcinoma were treated with TAR therapy (S-1; orally, 65 mg/m2/day, twice a day; vitamin A (retinol palmitate): 50, 000 I U/day, intra-musculary on each day of radiation; radiation: 1.5-2 Gy/day, 5 days/week). Histologic complete responders at 30-40 Gy continued TAR therapy up to 60-70 Gy. Nonresponders at 30-40 Gy underwent surgery. The overall 5-year survival and disease-specific 5-year survival rates were 50.5% and 59% respectively. The cumulative 3-year laryngeal preservation rate for stage I was 100%, 82.5% for stage II, 66.6% for stage III, and 35% for stage IV. Laryngeal preservation was fair in T1/T2 patients (81 %), but not satisfactory in T3/T4 patients (21.4%). S1 is administered orally, and TAR therapy can be conducted in the clinic with low toxicity. However, protocols with high intensity may be necessary to improve laryngeal preservation for locally advanced (T4) hypopharyngeal cancer.

AB - The objective of this study was to analyze the outcome of hypopharyngeal cancer patients who underwent triple combination treatment with S-1, vitamin A and radiation (TAR therapy), and to analyze the role of TAR therapy for treating locally advanced hypopharyngeal cancer patients. 146 patients (stage I: 10 cases, stage II: 22 cases, stage III: 23 cases, stage IV: 91 cases) with hypopharyngeal squamous cell carcinoma were treated with TAR therapy (S-1; orally, 65 mg/m2/day, twice a day; vitamin A (retinol palmitate): 50, 000 I U/day, intra-musculary on each day of radiation; radiation: 1.5-2 Gy/day, 5 days/week). Histologic complete responders at 30-40 Gy continued TAR therapy up to 60-70 Gy. Nonresponders at 30-40 Gy underwent surgery. The overall 5-year survival and disease-specific 5-year survival rates were 50.5% and 59% respectively. The cumulative 3-year laryngeal preservation rate for stage I was 100%, 82.5% for stage II, 66.6% for stage III, and 35% for stage IV. Laryngeal preservation was fair in T1/T2 patients (81 %), but not satisfactory in T3/T4 patients (21.4%). S1 is administered orally, and TAR therapy can be conducted in the clinic with low toxicity. However, protocols with high intensity may be necessary to improve laryngeal preservation for locally advanced (T4) hypopharyngeal cancer.

UR - http://www.scopus.com/inward/record.url?scp=84864019063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864019063&partnerID=8YFLogxK

M3 - Article

C2 - 22584327

AN - SCOPUS:84864019063

VL - 39

SP - 759

EP - 763

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 5

ER -